HomeCompareSNDD vs ABBV

SNDD vs ABBV: Dividend Comparison 2026

SNDD yields 20000000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SNDD wins by $1.378983907781291e+33M in total portfolio value
10 years
SNDD
SNDD
● Live price
20000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.378983907781291e+33M
Annual income
$1,365,233,528,321,427,000,000,000,000,000,000,000,000.00
Full SNDD calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SNDD vs ABBV

📍 SNDD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSNDDABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SNDD + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SNDD pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SNDD
Annual income on $10K today (after 15% tax)
$1,700,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$1,160,448,499,073,213,000,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SNDD beats the other by $1,160,448,499,073,213,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SNDD + ABBV for your $10,000?

SNDD: 50%ABBV: 50%
100% ABBV50/50100% SNDD
Portfolio after 10yr
$6.894919538906455e+32M
Annual income
$682,616,764,160,713,500,000,000,000,000,000,000,000.00/yr
Blended yield
99.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SNDD
No analyst data
Altman Z
-7.5
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SNDD buys
0
ABBV buys
0
No recent congressional trades found for SNDD or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSNDDABBV
Forward yield20000000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$1.378983907781291e+33M$102.3K
Annual income after 10y$1,365,233,528,321,427,000,000,000,000,000,000,000,000.00$24,771.77
Total dividends collected$1.3780804039422322e+33M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SNDD vs ABBV ($10,000, DRIP)

YearSNDD PortfolioSNDD Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$1,000,010,700$1,000,000,000.00$11,550$430.00+$1000.00MSNDD
2$46,730,541,974,066$46,729,471,962,616.81$13,472$627.96+$46730541.96MSNDD
3$1,020,456,630,513,561,600$1,020,406,628,833,649,400.00$15,906$926.08+$1020456630513.55MSNDD
4$10,413,549,150,437,309,000,000$10,412,457,261,842,660,000,000.00$19,071$1,382.55+$10413549150437308.00MSNDD
5$49,663,934,918,154,680,000,000,000$49,652,792,420,563,720,000,000,000.00$23,302$2,095.81+$49663934918154682368.00MSNDD
6$110,708,450,458,551,960,000,000,000,000$110,655,310,048,189,540,000,000,000,000.00$29,150$3,237.93+$1.1070845045855196e+23MSNDD
7$115,383,637,844,852,680,000,000,000,000,000$115,265,179,802,862,020,000,000,000,000,000.00$37,536$5,121.41+$1.1538363784485268e+26MSNDD
8$56,260,281,340,608,930,000,000,000,000,000,000$56,136,820,848,114,940,000,000,000,000,000,000.00$50,079$8,338.38+$5.626028134060893e+28MSNDD
9$12,850,821,925,106,690,000,000,000,000,000,000,000$12,790,623,424,072,240,000,000,000,000,000,000,000.00$69,753$14,065.80+$1.285082192510669e+31MSNDD
10$1,378,983,907,781,291,200,000,000,000,000,000,000,000$1,365,233,528,321,427,000,000,000,000,000,000,000,000.00$102,337$24,771.77+$1.378983907781291e+33MSNDD

SNDD vs ABBV: Complete Analysis 2026

SNDDStock

RedHawk Holdings Corp., through its subsidiaries, engages in sale and distribution of medical devices, and sale of branded generic pharmaceutical drugs primarily in the United States and the United Kingdom. It operates in three segments: Land & Hospitality, Medical Device and Pharmaceutical, and Other Services. The company manufactures and sells Sharps and Needle Destruction Devices; carotid artery digital non-contact thermometers; and Centri Controlled Entry System, a full body X-ray scanner. It also distributes WoundClot, a bleeding control medical device; Berrcom JXB178 infrared non-contact thermometers; and Zonis. In addition, RedHawk Holdings Corp. sells a line of face masks and face shields, including a level 1 single use disposable mask, a three layer level 3 cotton masks, and KN95 and N95 masks; an anti-fog and anti-static splash protection face shield; and a line of ultraviolet sanitation lights, including tabletop and handheld devices, as well as branded generic pharmaceuticals, such as Paracetamol, Glipizide, and Omeprazole. The company serves retail pharmacies, hospitals, physicians' offices, private and public healthcare clinics, corrections facilities, schools, veterinary clinics, emergency services, first responders, municipalities, and long term care facilities. In addition, it is involved in the commercial and residential property investment and leasing activities; sale of point of entry full-body security systems; and provision of specialized financial services. The company was formerly known as Independence Energy Corp. and changed its name to RedHawk Holdings Corp. in October 2015. RedHawk Holdings Corp. was incorporated in 2005 and is headquartered in Lafayette, Louisiana.

Full SNDD Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SNDD vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SNDD vs SCHDSNDD vs JEPISNDD vs OSNDD vs KOSNDD vs MAINSNDD vs JNJSNDD vs MRKSNDD vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.